Develops research, programs, and initiatives designed to envision and activate sustainable solutions leading to better health for individuals and communities worldwide.
The COVID 19 pandemic created an all-hands-on-deck call to scientists all over the globe to study fo
rmerly little known, post-viral illnesses.,
While this pandemic has created a tsunami of illness that has ravaged mankind, it has simultaneously created hope for millions.
, Long COVID and ME/CFS
Post-viral and post-infectious chronic illnesses aren’t new.
“The single biggest threat to man’s continued dominance on the planet is the virus.”—Joshua Lederber
g, renowned molecular biologist and Nobel Laureate,
Innovation will continue to provide new and more effective ways to fight our evolving enemy.
, One example is Orna Therapeutics, a company developing the next generation of RNA technology: circular RNA. Circular RNA technology was originally invented at MIT and has immense potential to address key limitations of mRNA.
While COVID-19 and recent natural disasters have demonstrated the fundamental resilience of the glob
al pharmaceutical supply chain, they have also revealed blind spots, such as growing health inequities, that threaten our ability to advance broader publ,
Responding to supply chain challenges requires adaptation and coordination.
, Addressing Health Equity Challenges and Opportunities
COVID-19 has reinforced that large-scale public health challenges can further dr